Immune-checkpoint inhibitors for the treatment of metastatic melanoma: a model of cancer immunotherapy

被引：73

作者：

Queirolo, Paola ^{[1
]}

Boutros, Andrea ^{[1
]}

Tanda, Enrica ^{[1
]}

Spagnolo, Francesco ^{[1
]}

Quaglino, Pietro ^{[2
]}

机构：

[1] IRCCS Osped Policlin San Martino, Skin Canc Unit, Genoa, Italy

[2] Univ Turin, Med Sch, Dept Med Sci, Dermatol Clin, Turin, Italy

来源：

SEMINARS IN CANCER BIOLOGY | 2019年 / 59卷

关键词：

Melanoma; Immunotherapy; Immune-checkpoint inhibitors; CTLA-4; PD-1; Biomarker; CUTANEOUS ADVERSE EVENTS; OPEN-LABEL; COMBINED NIVOLUMAB; TUMOR RESPONSE; CHECKMATE; 037; DOUBLE-BLIND; IPILIMUMAB; PEMBROLIZUMAB; SURVIVAL; PHASE-3;

D O I：

10.1016/j.semcancer.2019.08.001

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Melanoma has always been described as an immunogenic tumor. Despite that, until 2011 the standard of care in metastatic melanoma was chemotherapy, with low response rates and no clear impact on overall survival. Melanoma was the first cancer type to drive the use of immune-checkpoint inhibitors into clinical practice, which revolutionized the therapeutic paradigm not only in melanoma, but also in an increasing number of tumors. In this review, the preclinical bases and the main clinical studies that led to the approval of immune-checkpoint inhibitors in advanced melanoma will be described with insights on novel combinations of treatments and on prognostic and predictive biomarkers.

引用

页码：290 / 297

页数：8

共 72 条

[1]

Andtbacka RHI, 2013, J CLIN ONCOL, V31

[2]

Ascierto A., 2018, KEYNOTE 022 3

[3] Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Three-Year Follow-up of a Randomized Phase 3 Trial [J].

Ascierto, Paolo A. ;

Long, Georgina V. ;

Robert, Caroline ;

Brady, Benjamin ;

Dutriaux, Caroline ;

Di Giacomo, Anna Maria ;

Mortier, Laurent ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Kalinka-Warzocha, Ewa ;

Savage, Kerry J. ;

Hernberg, Micaela M. ;

Lebbe, Celeste ;

Charles, Julie ;

Mihalcioiu, Catalin ;

Chiarion-Sileni, Vanna ;

Mauch, Cornelia ;

Cognetti, Francesco ;

Ny, Lars ;

Arance, Ana ;

Svane, Inge Marie ;

Schadendorf, Dirk ;

Gogas, Helen ;

Saci, Abdel ;

Jiang, Joel ;

Rizzo, Jasmine ;

Atkinson, Victoria .

JAMA ONCOLOGY, 2019, 5 (02) :187-194

[4] Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial [J].

Ascierto, Paolo A. ;

Del Vecchio, Michele ;

Robert, Caroline ;

Mackiewicz, Andrzej ;

Chiarion-Sileni, Vanna ;

Arance, Ana ;

Lebbe, Celeste ;

Bastholt, Lars ;

Hamid, Omid ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Garbe, Claus ;

Loquai, Carmen ;

Dreno, Brigitte ;

Thomas, Luc ;

Grob, Jean-Jacques ;

Liszkay, Gabriella ;

Nyakas, Marta ;

Gutzmer, Ralf ;

Pikiel, Joanna ;

Grange, Florent ;

Hoeller, Christoph ;

Ferraresi, Virginia ;

Smylie, Michael ;

Schadendorf, Dirk ;

Mortier, Laurent ;

Svane, Inge Marie ;

Hennicken, Delphine ;

Qureshi, Anila ;

Maio, Michele .

LANCET ONCOLOGY, 2017, 18 (05) :611-622

[5] Dabrafenib, trametinib and pembrolizumab or placebo in BRAF-mutant melanoma [J].

Ascierto, Paolo Antonio ;

Ferrucci, Pier Francesco ;

Fisher, Rosalie ;

Del Vecchio, Michele ;

Atkinson, Victoria ;

Schmidt, Henrik ;

Schachter, Jacob ;

Queirolo, Paola ;

Long, Georgina V. ;

Di Giacomo, Anna Maria ;

Svane, Inge Marie ;

Lotem, Michal ;

Bar-Sela, Gil ;

Couture, Felix ;

Mookerjee, Bijoyesh ;

Ghori, Razi ;

Ibrahim, Nageatte ;

Moreno, Blanca Homet ;

Ribas, Antoni .

NATURE MEDICINE, 2019, 25 (06) :941-+

[6] Initial efficacy of anti-lymphocyte activation gene-3 (anti-LAG-3; BMS-986016) in combination with nivolumab (nivo) in pts with melanoma (MEL) previously treated with anti-PD-1/PD-L1 therapy. [J].

Ascierto, Paolo Antonio ;

Melero, Ignacio ;

Bhatia, Shailender ;

Bono, Petri ;

Sanborn, Rachel E. ;

Lipson, Evan J. ;

Callahan, Margaret K. ;

Gajewski, Thomas ;

Gomez-Roca, Carlos A. ;

Hodi, F. Stephen ;

Curigliano, Giuseppe ;

Nyakas, Marta ;

Preusser, Matthias ;

Koguchi, Yoshinobu ;

Maurer, Matthew ;

Clynes, Raphael ;

Mitra, Priyam ;

Suryawanshi, Satyendra ;

Munoz-Couselo, Eva .

JOURNAL OF CLINICAL ONCOLOGY, 2017, 35

[7] Immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome: a paradigm of immunodeficiency with autoimmunity [J].

Barzaghi, Federica ;

Passerini, Laura ;

Bacchetta, Rosa .

FRONTIERS IN IMMUNOLOGY, 2012, 3

[8] A First-in-Human Study and Biomarker Analysis of NKTR-214, a Novel 1L2Rβγ-Biased Cytokine, in Patients with Advanced or Metastatic Solid Tumors [J].

Bentebibel, Salah-Eddine ;

Hurwitz, Michael E. ;

Bernatchez, Chantale ;

Haymaker, Cara ;

Hudgens, Courtney W. ;

Kluger, Harriet M. ;

Tetzlaff, Michael T. ;

Tagliaferri, Mary A. ;

Zalevsky, Jonathan ;

Hoch, Ute ;

Fanton, Christie ;

Aung, Sandra ;

Hwu, Patrick ;

Curti, Brendan D. ;

Tannir, Nizar M. ;

Sznol, Mario ;

Diab, Adi .

CANCER DISCOVERY, 2019, 9 (06) :711-721

[9] Immune related adverse events associated with anti-CTLA-4 antibodies: systematic review and meta-analysis [J].

Bertrand, Anne ;

Kostine, Marie ;

Barnetche, Thomas ;

Truchetet, Marie-Elise ;

Schaeverbeke, Thierry .

BMC MEDICINE, 2015, 13

[10] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline [J].

Brahmer, Julie R. ;

Lacchetti, Christina ;

Schneider, Bryan J. ;

Atkins, Michael B. ;

Brassil, Kelly J. ;

Caterino, Jeffrey M. ;

Chau, Ian ;

Ernstoff, Marc S. ;

Gardner, Jennifer M. ;

Ginex, Pamela ;

Hallmeyer, Sigrun ;

Chakrabarty, Jennifer Holter ;

Leighl, Natasha B. ;

Mammen, Jennifer S. ;

McDermott, David F. ;

Naing, Aung ;

Nastoupil, Loretta J. ;

Phillips, Tanyanika ;

Porter, Laura D. ;

Puzanov, Igor ;

Reichner, Cristina A. ;

Santomasso, Bianca D. ;

Seigel, Carole ;

Spira, Alexander ;

Suarez-Almazor, Maria E. ;

Wang, Yinghong ;

Weber, Jeffrey S. ;

Wolchok, Jedd D. ;

Thompson, John A. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) :1714-+

← 1 2 3 4 5 6 7 8 →